analysis to compare the two strategies: 1) direct prostate biopsies (TRUS-Bx) and 2) percent free PSA testing prior to TRUS-Bx. A systematic review of 855 patients with PSA levels of 4.0-10.0 ng/ml and normal DRE enrolled in a single medical institute from Jan 2002 to December 2005 was conducted. The outcome measures were the incremental cost-effectiveness ratio, and costs were calculated through activityaccumulation costing based on National Insurance Scheme Bill Size. A one-way sensitivity analysis was undertaken. The effectiveness was measured by means of the number of detected cases and actual cases (detected cases minus lost cases). A threshold analysis is used to illustrate the value of a given variable of which the two strategies have equal outcomes or costs. Results: The strategy of percent free PSA with TRUS-Bx was dominant and found to be the most cost-effective. The incremental cost-effectiveness ratio for free PSA + TRUS-Bx compared with TRUS-Bx was USD 3,871.58. Strategy 2 (TRUS-Bx) would be more cost-effective if the cost of percent free PSA increased to USD 36.78 or if prostate cancer prevalence increased to 42%. ConClusions: The use of percent free PSA prior to TRUS-Bx is the most costeffective diagnostic strategy and will become more cost-effective as prostate cancer prevalence increases in the ageing population and the free PSA test costs down.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.